Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
(HealthDay News) — For hypogonadal men, long-term testosterone therapy seems not to be associated with increased incidence of prostate cancer, according to research published in The Journal of Urology.
Ahmad Haider, MD, PhD, from the University Clinics Muenster in Germany, and colleagues reviewed data from three parallel, prospective registry studies involving 1,023 hypogonadal men receiving testosterone therapy.
The study cohorts were treated by urologists (two cohorts) and at an academic andrology center (one cohort). Patients were followed for a median of 5 years and the incidence of prostate cancer and post-prostatectomy outcomes were assessed.
The researchers found that in the two urology settings, 11 patients were diagnosed with prostate cancer, at proportions of 2.3% and 1.5%, respectively. The incidence was 54.4 and 30.7 per 10,000 patient-years, respectively. There were no reports of prostate cancer at the andrology center.
“Testosterone therapy in hypogonadal men does not increase the risk of prostate cancer,” the authors write. “If guidelines for testosterone therapy are properly applied, testosterone treatment is safe in hypogonadal men.”
Several authors disclosed financial ties to the pharmaceutical industry.
